Compare · LIPO vs NVO
LIPO vs NVO
Side-by-side comparison of Lipella Pharmaceuticals Inc. (LIPO) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LIPO and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $215.95B.
- Over the past year, LIPO is up 0.0% and NVO is down 32.0% - LIPO leads by 32.0 points.
- NVO has been more active in the news (5 items in the past 4 weeks vs 1 for LIPO).
- NVO has more recent analyst coverage (25 ratings vs 0 for LIPO).
- Company
- Lipella Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- $2.30-15.44%
- $48.78+1.22%
- Market cap
- -
- $215.95B
- 1M return
- +0.00%
- +2.89%
- 1Y return
- +0.00%
- -31.99%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 1
- 5
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest LIPO
- Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Financial Statements and Exhibits
- Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Financial Statements and Exhibits
- Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update
- SEC Form 10-Q filed by Lipella Pharmaceuticals Inc.
- Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update
- Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update
- Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus
- Lipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen Planus
- SEC Form 10-Q filed by Lipella Pharmaceuticals Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S